Cellectis S.A. (CLLS)Healthcare | Biotechnology | Paris, France | NasdaqGM
3.40 USD
-0.11
(-3.139%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.41 |
Hot Take ↕ | Aug. 22, 2026, 4:01 a.m. EDT
The investment case here is severely compromised by a deteriorating business trajectory. Revenue has contracted by nearly 62% year-over-year, and the company is burning cash with negative operating margins and a return on equity of nearly -95%. Despite a recent price bounce, the multi-year history shows a catastrophic decline of over 89%, indicating the market has already priced in a structural failure of the current business model. The lack of any dividend payout eliminates income as a buffer, leaving investors entirely exposed to capital loss. While the analyst consensus remains 'Buy' with a target price significantly higher than the current level, this appears to be a speculative bet on a turnaround that the fundamentals currently do not support. The options market confirms this skepticism, with traders placing substantial bets on further downside. This is a high-risk situation where the gap between the optimistic analyst targets and the grim reality of shrinking revenues and losses is too wide to ignore. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.175986 |
| AutoETS | 0.179521 |
| MSTL | 0.182502 |
| AutoTheta | 0.202656 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 3.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.574 |
| Excess Kurtosis | -0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 195.656 |
| Revenue per Share | 0.635 |
| Market Cap | 342,384,128 |
| Forward P/E | -5.48 |
| Beta | 2.75 |
| Profit Margins | -102.34% |
| Website | https://www.cellectis.com |
As of Aug. 22, 2026, 4:01 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by heavy put open interest at the $2.50 strike across multiple expirations compared to minimal call activity. While some out-of-the-money calls exist at higher strikes ($5.00-$7.50), the volume and open interest concentration in the puts suggests a bearish bias or a hedging strategy against further declines rather than a bullish momentum play.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.37258685 |
| Address1 | 8, rue de la Croix Jarry |
| All Time High | 50.0 |
| All Time Low | 0.963 |
| Ask | 2.99 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 18,390 |
| Average Daily Volume3 Month | 28,304 |
| Average Volume | 28,304 |
| Average Volume10Days | 18,390 |
| Beta | 2.752 |
| Bid | 2.8 |
| Bid Size | 1 |
| Book Value | 0.565 |
| City | Paris |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.4 |
| Current Ratio | 1.366 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.57 |
| Day Low | 3.4 |
| Debt To Equity | 195.656 |
| Display Name | Cellectis |
| Earnings Call Timestamp End | 1,774,008,000 |
| Earnings Call Timestamp Start | 1,774,008,000 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -46,677,000 |
| Ebitda Margins | -0.73135 |
| Enterprise To Ebitda | -3.446 |
| Enterprise To Revenue | 2.52 |
| Enterprise Value | 160,837,744 |
| Eps Forward | -0.62 |
| Eps Trailing Twelve Months | -0.62 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.96886 |
| Fifty Day Average Change | 0.43114018 |
| Fifty Day Average Change Percent | 0.14522079 |
| Fifty Two Week Change Percent | 37.258686 |
| Fifty Two Week High | 5.48 |
| Fifty Two Week High Change | -2.08 |
| Fifty Two Week High Change Percent | -0.37956202 |
| Fifty Two Week Low | 2.35 |
| Fifty Two Week Low Change | 1.0500002 |
| Fifty Two Week Low Change Percent | 0.4468086 |
| Fifty Two Week Range | 2.35 - 5.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,427,203,800,000 |
| Float Shares | 46,787,081 |
| Forward Eps | -0.62 |
| Forward P E | -5.483871 |
| Free Cashflow | 107,701,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 224 |
| Fullday Change | -0.1102 |
| Fullday Change Percent | -3.13942 |
| Fullday Price | 3.41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 63,823,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.15359001 |
| Implied Shares Outstanding | 100,701,207 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. |
| Long Name | Cellectis S.A. |
| Market | us_market |
| Market Cap | 342,384,128 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1216695 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -65,314,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 363,819,777 |
| Number Of Analyst Opinions | 5 |
| Open | 3.48 |
| Operating Cashflow | -41,625,000 |
| Operating Margins | -3.4068701 |
| Payout Ratio | 0.0 |
| Phone | 33 1 81 69 16 00 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.41 |
| Post Market Time | 1,787,947,451 |
| Previous Close | 3.5102 |
| Price Hint | 4 |
| Price To Book | 6.0176992 |
| Price To Sales Trailing12 Months | 5.3645883 |
| Profit Margins | -1.02336 |
| Quick Ratio | 1.336 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.11019993 |
| Regular Market Change Percent | -3.1394203 |
| Regular Market Day High | 3.57 |
| Regular Market Day Low | 3.4 |
| Regular Market Day Range | 3.4 - 3.57 |
| Regular Market Open | 3.48 |
| Regular Market Previous Close | 3.5102 |
| Regular Market Price | 3.4 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 5,600 |
| Return On Assets | -0.11668 |
| Return On Equity | -0.94536 |
| Revenue Growth | -0.621 |
| Revenue Per Share | 0.635 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 72,701,207 |
| Shares Percent Shares Out | 0.003 |
| Shares Short | 301,671 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 289,618 |
| Short Name | Cellectis S.A. |
| Short Percent Of Float | 0.0055 |
| Short Ratio | 17.73 |
| Source Interval | 15 |
| Symbol | CLLS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.6 |
| Target Median Price | 8.0 |
| Total Cash | 166,686,000 |
| Total Cash Per Share | 2.293 |
| Total Debt | 80,350,000 |
| Total Revenue | 63,823,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.70254 |
| Two Hundred Day Average Change | -0.30253983 |
| Two Hundred Day Average Change Percent | -0.08171143 |
| Type Disp | Equity |
| Volume | 5,600 |
| Website | https://www.cellectis.com |
| Zip | 75,013 |